AFP and hepatocellular carcinoma: In comparison with the PIVKA‐II, the clinical efficacy of the AFP is under constant suspicion; one Korean study in 2009 even presented that the serum PIVKA‐II level was an independent risk factor to the outcome of HBV related HCC while the AFP was not.31